Stocks and Investing
by (remove) : Aydin Huseynov
RSSJSONXMLCSV
Stocks and Investing
by (remove) : Aydin Huseynov
RSSJSONXMLCSV
Mon, September 16, 2024
Tue, May 14, 2024
Mon, April 29, 2024
Thu, April 18, 2024
Fri, April 5, 2024
Thu, March 14, 2024
Thu, February 8, 2024
Fri, December 1, 2023
Tue, October 10, 2023
Mon, June 5, 2023
Fri, April 28, 2023
Tue, March 7, 2023
Wed, October 26, 2022
Thu, September 15, 2022
Tue, August 23, 2022
Wed, August 3, 2022
Wed, July 27, 2022
Fri, May 27, 2022
Mon, May 2, 2022
Tue, March 8, 2022
Fri, December 10, 2021
Fri, August 20, 2021
Thu, March 19, 2020

Aydin Huseynov Upgraded (ACRV) to Strong Buy and Held Target at $16 on, Sep 16th, 2024


Published on 2024-10-28 14:16:19 - WOPRAI, Aydin Huseynov
  Print publication without navigation


Aydin Huseynov of Ladenburg Thalmann, Upgraded "Acrivon Therapeutics, Inc." (ACRV) to Strong Buy and Held Target at $16 on, Sep 16th, 2024.

Aydin, nor any peers, have made any analyst calls on ACRV in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources